KouShiCare utilizes DWV LLLT Technology to Treat Dry Eyes

KouShiCare, a leading innovator in healthcare technology, announced an advancement in the treatment of dry eye disease. The company's latest device harnesses the power of DWV Low-Level Laser Therapy (LLLT) technology, marking a significant step forward in light-based ocular care.

Approximately 344 million people worldwide suffer from dry eye disease. This condition causes discomfort, blurred vision, and a significant decline in quality of life. Traditional treatments, like eye drops and medications, often offer only temporary relief and may not effectively address underlying gland dysfunction.

KouShiCare's latest innovation, the LuminEyes Light Therapy Device, utilizes LLLT (Low-Level Light Therapy) and DWV LLLT (Dual-Wavelength Low-Level Light Therapy) technology to promote cellular metabolism and tissue repair. The LLLT uses low-power LEDs, no more than 100mW/cm², to deliver precise red or near-infrared light to biological tissues while preventing thermal damage. Additionally, by irradiating the eyelids and Meibomian glands with LEDs at 600nm (visible red light) ～ 900nm (near-infrared light), DWV LLLT stimulates ocular metabolism through PBM (photobiomodulation), harnessing biological regulatory effects to enhance eye health.

Numerous research and clinical studies have demonstrated that Red Light Therapy effectively softens blocked Meibomian gland lipids, improves the tear film's lipid layer, alleviates dryness and the sensation of a foreign body, and enhances tear film stability. Compared to traditional treatments, it delivers more significant results while offering greater convenience and comfort.